DOCSLIB.ORG

Trendsrx®Drug Pipeline & News

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Trendsrx®Drug Pipeline & News TrendsRx® September 2009 TrendsRx®Drug Pipeline & News Volume 5, Number 9 Pipeline Highlights: July 29, 2009 – August 27, 2009 and Recent Selected Health Care News Highlights Selected Generic Product Approvals/Launches1,2* azelastine Dosage Form; Strength Solution, ophthalmic; 0.05% (Optivar®) Approval Date† August 3, 2009 Anticipated Launch Date‡ December 1, 2009 Comments The reference brand is used for the treatment of itching of the eye associated with allergic conjunctivitis. This product is AT-rated and will be available from a single generics manufacturer. oxaliplatin Dosage Form; Strengths Injection, intravenous infusion; 50 mg/vial and 100 mg/vial (Eloxatin®) Approval Date† August 11, 2009 Launch Date‡ August 11, 2009 Comments The reference brand, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for: - adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor - treatment of advanced colorectal cancer This product is AP-rated and will be available from multiple generics manufacturers. The manufacturer of the reference brand is involved in litigation with manufacturers of the generic drug and the FDA concerning the FDA’s approval of generic brands. tacrolimus Dosage Form; Strengths Capsule, oral; 0.5 mg, 1 mg and 5 mg (Prograf®) Approval Date† August 10, 2009 Launch Date‡ August 11, 2009 Comments The reference brand is indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver, kidney or heart transplants. This product is AB-rated and will be available from a single generics manufacturer. The manufacturer of this product and the manufacturer of the reference drug are involved in ongoing litigation. clonidine TDS Dosage Form; Strengths Extended-release film, transdermal; 0.1 mg/24 hours, 0.2 mg/24 hours and 0.3 mg/24 hours (Catapress-TTS®) Approval Date† August 18, 2009 Launch Date‡ August 20, 2009 Comments The reference brand is indicated for the treatment of hypertension. This product is AB-rated and will be available from a single generics manufacturer. clindamycin Dosage Form; Strength Gel; topical; 1% clindamycin/5% benzoyl peroxide phosphate/benzoyl Approval Date† August 11, 2009 peroxide (BenzaClin®) Launch Date‡ August 27, 2009 Comments The reference brand is used for the topical treatment of acne vulgaris. This product is AB-rated and will be available from a single generics manufacturer. Continued on next page www.caremark.com Recent New Drug Application (NDA) Approvals1,2* Tyvaso™ Dosage Form; Strength Solution, inhalation; 2.9 mL ampule containing 1.74 mg treprostinil (0.6 mg/mL) (treprostinil) Indication For the treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III symptoms, to increase walk distance United Therapeutics Approval Date July 30, 2009 Corporation/ Anticipated Launch Date‡ Early September 2009 Lung Rx, Inc. Comments This is a new formulation of an already approved drug. Invega® Sustenna™ Dosage Form; Strengths Extended-release suspension for intramuscular injection; 39 mg/0.25 mL, 78 mg/0.5 mL, 117 mg/0.75 mL, 156 mg/1 mL (paliperidone and 234 mg/1.5 mL palmitate) Indications For the acute and maintenance treatment of schizophrenia in adults Ortho-McNeil-Janssen Approval Date July 31, 2009 Pharmaceuticals, Anticipated Launch Date‡ Third quarter 2009 Inc. Comments This is a new formulation of an already approved drug. Lipsovir® Dosage Form; Strength(s) Cream, topical; Strength(s) not available at time of publication (acyclovir/ Indications For the early treatment of recurrent herpes labialis (cold sores), to reduce the likelihood of ulcerative cold sores, and to hydrocortisone) shorten lesion healing time in adults and children 12 years of age and older Approval Date August 3, 2009 Medivir Anticipated Launch Date‡ Third quarter 2009 Livalo® Dosage Form; Strengths Tablet, oral; 1 mg, 2 mg and 4 mg (pitavastatin) Indications For the primary treatment of hypercholesterolemia and combined dyslipidemia Kowa Pharmaceuticals Approval Date August 3, 2009 America Inc. Anticipated Launch Date‡ First quarter 2010 Embeda™ Dosage Form; Strengths Extended-release capsule, oral; 20 mg/0.8mg, 30 mg/1.2 mg, 50 mg/2 mg, 60 mg/2.4 mg, 80 mg/3.2 mg and 100 mg/4 mg (morphine/ Indication For the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an naltrexone) extended period of time. Embeda is not intended for use as a PRN analgesic. King Approval Date August 13, 2009 Pharmaceuticals, Inc. Anticipated Launch Date‡ September, 2009 Saphris® (asenapine) Dosage Form; Strengths Tablet, sublingual; 5 mg and 10 mg Indications For the acute treatment of schizophrenia in adults and acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults Schering-Plough Approval Date August 13, 2009 Corporation Anticipated Launch Date‡ Fourth quarter 2009 Sabril® (vigabatrin) Dosage Forms; Strengths Powder for solution, oral; 500 mg Tablet, oral; 500 mg Indication - For use as monotherapy in pediatric patients one month to two years of age with infantile spasms (IS) for whom the potential benefits outweigh the potential risk of vision loss - For use as an adjunctive therapy for adult patients with refractory complex partial seizures (CPS) who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss Approval Date August 21, 2009 Lundbeck Inc. Anticipated Launch Date‡ Third quarter 2009 Continued on next page www.caremark.com Recent Product Launches1,2* Effient™ (prasugrel) Dosage Form; Strengths Tablet, oral; 5 mg and 10 mg Indications For the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI) as follows: Daiichi Sankyo Co., - Patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI) Ltd/ Eli Lilly and - Patients with ST-elevation myocardial infarction (STEMI) when managed with either primary or delayed PCI Company Launch Date‡ August 5, 2009 Ilaris® (canakinumab) Dosage Form; Strength Injection, subcutaneous; 180 mg/6 mL vial Indication For the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) in adults and children 4 years of age and older, including Novartis - Familial Cold Autoinflammatory Syndrome (FCAS) Pharmaceuticals - Muckle-Wells Syndrome (MWS) Corporation Launch Date‡ August 7, 2009 Onglyza™ (saxagliptin) Dosage Form; Strengths Tablet, oral; 2.5 mg and 5 mg Bristol-Myers Indication For use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus Squibb/AstraZeneca Launch Date‡ August 7, 2009 Edluar™ (zolpidem) Dosage Form; Strengths Tablet, sublingual; 5 mg and 10 mg Meda Indication For the short-term treatment of insomnia characterized by difficulties with sleep initiation Pharmaceuticals/ Launch Date‡ August 11, 2009 Orexo Plan B® One-Step Dosage Form; Strength Tablet, oral; 1.5 mg (levonorgestrel) Indication For prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure Duramed Launch Date‡ August 11, 2009 Pharmaceuticals Acuvail™ Dosage Form; Strength Solution, ocular; 0.45% (ketorolac Indication For the treatment of pain and inflammation following cataract surgery tromethamine) Launch Date‡ August 11, 2009 Allergan, Inc Cetraxal® Otic Dosage Form; Strength Solution, otic; 0.2% (ciprofloxacin) Indication For the treatment of acute otitis externa due to susceptible isolates of Pseudomonas aeruginosa or Staphylococcus aureus SALVAT USA Inc. Launch Date‡ August 11, 2009 Colcrys™ (colchicine) Dosage Form; Strength Tablet, oral; 0.6 mg Mutual Indications For the treatment of familial Mediterranean fever (FMF) in adults and children 4 years of age and older and the treatment of Pharmaceutical acute gout flares when taken at the first sign of a flare Company, Inc. Launch Date‡ August 14, 2009 Recent Biologic License Application (BLA) Approvals1,2* Extavia® Dosage Form; Strength Injection, subcutaneous; 0.3 mg (interferon beta-1b) Indication For the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations Novartis Approval Date August 14, 2009 Pharmaceuticals Launch Date‡ Third quarter 2009 Corporation Hiberix® Dosage Form; Strength Solution for injection, intramuscular; 0.5 mL dose (Haemophilus b Indication For active immunization as a booster dose for the prevention of invasive disease caused by Haemophilus influenzae type b Conjugate Vaccine in children 15 months through 4 years of age (prior to fifth birthday) [Tetanus Toxoid Approval Date August 19, 2009 Conjugate]) Launch Date‡ Early September 2009 GlaxoSmithKline Continued on next page www.caremark.com Recent Supplemental New Drug Application (sNDA) Approvals1,2* Invega® Dosage Form Extended-release tablet, oral (paliperidone) Indications For the acute treatment of schizoaffective disorder as monotherapy and the acute treatment of schizoaffective disorder as an adjunct to mood stabilizers and/or antidepressants ALZA Corporation Approval Date July 31, 2009 and Janssen Cilag Comments This is a new indication for an already approved product. Manufacturing, LLC This product was previously indicated for the acute and maintenance treatment of schizophrenia only. Avastin® Dosage Form Single use vial, intravenous infusion (bevacizumab) Indication
Load more

Recommended publications
  • No. 33981 2 No
    Pretoria, 4 February 2011 Februarle No. 33981 2 No. 33981 GOVERNMENT GAZETTE, 4 FEBRUARY 2011 IMPORTANT NOTICE The Government Printing Works will not be held responsible for faxed documents not received due to errors on the fax machine or faxes received which are unclear or incomplete. Please be advised that an "OK" slip, received from a fax machine, will not be accepted as proof that documents were received by the GPW for printing. If documents are faxed to the GPW it will be the sender's respon­ sibility to phone and confirm that the documents were received in good order. Furthermore the Government Printing Works will also not be held responsible for cancellations and amendments which have not been done on original documents received from clients. CONTENTS INHOUD Bladsy Koerant Page Gazette No. No. No. No. No. No. GENERAL NOTICE ALGEMENEKENNISGEWING Health, Department of Gesondheld, Departement van General Notice A/gemene Kennisgewing 58 Medicines and Related Substances Act 58 Wet op Beheer van Medisyne en (101/1965): Medicines Control Council: Verwante Stowwe (101/1965): Conditions of registration of a medicine Medisynebeheerraad: Voorwaardes vir in terms of the provisions of section die registrasie van 'n medisyne in terme 15 (7) ..................................................... .. 3 33981 van die bepalings van artikel 15 (7) ........ 4 33981 STAATSKOERANT, 4 FEBRUARIE 2011 No. 33981 3 GENERAL NOTICE ALGEMENE KENNISGEWING NOTICE 58 OF 2011 MEDICINES CONTROL COUNCIL CONDITIONS OF REGISTRATION OF A MEDICINE IN TERMS OF THE PROVISIONS OF SECTION 15(7) OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 1. The applicant shall ensure that the medicine is manufactured and controlled in terms of the current Good Manufacturing Practices as determined by Council 2.
    [Show full text]
  • IN the UNITED STATES DISTRICT COURT for the DISTRICT of DELAWARE ALZA CORPORATION and JANSSEN PHARMACEUTICALS, INC., Plaintiffs
    Case 1:16-cv-00914-UNA Document 3 Filed 10/07/16 Page 1 of 20 PageID #: 24 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ALZA CORPORATION and ) JANSSEN PHARMACEUTICALS, INC., ) ) Plaintiffs, ) ) v. ) Civil Action No. ____________ ) REDACTED PUBLIC VERSION AMNEAL PHARMACEUTICALS OF ) NEW YORK, LLC and ) AMNEAL PHARMACEUTICALS LLC, ) ) Defendants. ) COMPLAINT In this patent infringement action, Plaintiffs ALZA Corporation ("ALZA") and Janssen Pharmaceuticals, Inc. (collectively "Plaintiffs"), for their complaint against Defendants Amneal Pharmaceuticals of New York, LLC ("Amneal Pharms. NY") and Amneal Pharmaceuticals LLC ("Amneal Pharms. LLC") (collectively, "Amneal"), allege as follows: NATURE OF THE ACTION 1. This is an action for patent infringement under the patent laws of the United States, Title 35, United States Code, in response to, inter alia, the submission by Amneal of Abbreviated New Drug Application ("ANDA") No. 207515, with the U.S. Food and Drug Administration ("FDA") seeking approval to manufacture and sell a generic version of CONCERTA® prior to the expiration of U.S. Patent No. 8,163,798 ("the '798 patent") and U.S. Patent No. 9,144,549 ("the '549 patent"). PARTIES 2. Plaintiff ALZA is a Delaware corporation, having its principal place of business at 700 Eubanks Drive, Vacaville, California 95688. Case 1:16-cv-00914-UNA Document 3 Filed 10/07/16 Page 2 of 20 PageID #: 25 REDACTED PUBLIC VERSION 3. Plaintiff Janssen Pharmaceuticals, Inc. ("Janssen") is a Pennsylvania corporation, having a place of business at 1125 Trenton-Harbourton Road, Titusville, New Jersey 08560. 4. On information and belief, Defendant Amneal Pharms. LLC is a limited liability company organized under the laws of the State of Delaware and has a place of business at 400 Crossing Boulevard, Bridgewater, NJ 08807.
    [Show full text]
  • Management Team
    Management Team Bruce C. Cozadd Executive Chairman Bruce Cozadd joined Jazz Pharmaceuticals at its inception. From 2001 until he joined Jazz Pharmaceuticals, Mr. Cozadd served as a consultant to companies in the biopharmaceutical industry. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company now owned by Johnson & Johnson, most recently as its Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporation he held the roles of Chief Financial Officer and Vice President, Corporate Planning and Analysis. Mr. Cozadd received a B.S. from Yale University and an M.B.A. from the Stanford Graduate School of Business. Mr. Cozadd serves on the boards of Cerus Corporation, a biopharmaceutical company; Threshold Pharmaceuticals, a biotechnology company; and The Nueva School and Stanford Hospital and Clinics, both non-profit organizations. Samuel R. Saks, MD Chief Executive Officer Samuel Saks, M.D., joined Jazz Pharmaceuticals at its inception. From 2001 until he joined Jazz Pharmaceuticals, Dr. Saks was Company Group Chairman of ALZA Corporation and served as a member of the Johnson & Johnson Pharmaceutical Group Operating Committee. From 1992 until 2001, he held various positions with ALZA Corporation, most recently as its Chief Medical Officer and Group Vice President, where he was responsible for clinical and commercial activities. Dr. Saks received a B.S. and an M.D. from the University of Illinois. Dr. Saks serves on the board of Trubion Pharmaceuticals and Cougar Biotechnology. Robert M. Myers President Robert Myers joined Jazz Pharmaceuticals at its inception and was appointed as Jazz Pharmaceuticals’ President in March 2007.
    [Show full text]
  • Notice Under S66 of the Commerce Act 1986 Application by Johnson & Johnson to Acquire the Stock, Assets and Business Of
    PUBLIC COPY Notice under s66 of the Commerce Act 1986 Application by Johnson & Johnson to acquire the stock, assets and business of the Consumer Healthcare division of Pfizer Inc. COMMERCE ACT 1986: BUSINESS ACQUISITION SECTION 66: NOTICE SEEKING CLEARANCE 28 September 2006 The Registrar Business Acquisitions and Authorisations Commerce Commission PO Box 2351 Wellington Pursuant to s66(1) of the Commerce Act 1986 notice is hereby given seeking clearance of a proposed business acquisition. 518689_1.DOC 2 CONTENTS EXECUTIVE SUMMARY PART 1: TRANSACTION DETAILS 1 The business acquisition for which clearance is sought 2 The person giving this notice 3 Confidentiality 4 Participants 5 Interconnected and associated persons 6 Beneficial interests 7 Links between participants 8 Common directorships 9 Business activities of the participants 10 Reasons for the proposed acquisition PART II: IDENTIFICATION OF MARKETS AFFECTED 11 Horizontal aggregation 12 Differentiated product markets 13 Differentiated product markets 14 Vertical integration 15 Other business acquisitions PARTS III, IV AND V: CONSTRAINTS ON MARKET POWERS BY EXISTING AND POTENTIAL COMPETITION AND OTHER POTENTIAL CONSTRAINTS 16 Allergy medication 17 Products for the treatment of worms 18 Thrush treatment CERTIFICATE APPENDICES 1. Heartburn and indigestion remedies (MYLANTA and MOTILIUM) 2. Worm treatments (COMBANTRIN, VERMOX) 3. Cold, flu, nasal decongestant, cough relief and sort throat medications (CODRAL, SINUTAB, SUDAFED, BENADRYL, BRONDECON) 4. Allergy relief products (ACTIFED, SINUTAB, SUDAFED, VISINE, LIVOSTIN) 518689_1.DOC 3 5. Thrush treatments (DIFLUCAN ONE, DAKTARIN, DAKTAGOLD, NIZORAL, SPORANOX) 6. Shampoo (PREGAINE, ROGAINE, NEUTROGENA, JOHNSON’S BABY SHAMPOO) 7. Hand hygiene (PURELL and MICRO SHIELD) 8. Competitor worm treatment products 9. Multinational pharmaceutical businesses: GlaxoSmithKline, Douglas Pharmaceuticals, Alphapharm, Bayer Group 10.
    [Show full text]
  • Memorandum JUL 1 6 201D
    Memorandum Subject Date Additional Quota Letters Received by July 15, 2010 (DFN: 630-08.2) JUL 1 6 201D To From Christine A. Sanncrud. Ph.D., Chief "Barbar• J.Illoockholdt, Chief Drug & Chemical Evaluation Section Regul• torn Section Office of Diverison Control Off cL rl Diversion Control On July 15. 2010, this section received your e-mail requesting a review of seventeen (17) quota applications from sixteen (16) registered manufacturers to determine if there arc any pending administrative/legal actions against these applicants and to advise ODE of the findings. ODOR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations. QUOTA APPLICANTS wan NO ADVERSE OR DEROGATORY INFORMATIO N Novartis Consumer I lealth Lincoln (10345) (b)(4);(b)(7)(E) Baxter (10346) Generics Bidco li bda Vintage (10347) Noramco Delaware (10348) Pharmaceuticals International inc. (10349) Pharmedium (10351) Pharmedium (10352) Rhodes (10356) Bio-Pharm (10357) Patheon (10358) Patheon (10359) Watson (10361) B & B (10363) lospira. Inc. NC (10364) Epic Pharma (10366) Mallinckrodt I lobart (10367) Chemtos (10368) Vol. II Page 55 2 Per consultation with the field offices. DEA does not have sufficient grounds to limit, restrict. or deny quota requests from these registrants. Based on this information. ODG suggests that you proceed with the completion of the quota applications. If you have any questions pertaining to this information. please feel free to contact me (b)(6);(b)(7)( or SC C) (b)(6);(b)(7)(C) Vol. II Page 56 Memorandum Subject Date Additional Quota Letters Received as of July 19, 201() (DFN: 630-08.2) stir 2 8 2010,., To Fr ,./"./ Christine A.
    [Show full text]
  • Management Liability Focus Johnson & Johnson 1
    Insured Profile Report – Management Liability Focus Johnson_________________________________________________________________________ & Johnson Company Profile Credit Details Location 1 Johnson and Johnson Plz Overall Credit Risk High Risk New Brunswick, NJ www.jnj.com Number of Legal Derogatory 84 Company Type Public Items Liability Amount $322,285.00 Formerly Known As N/A Experian Intelliscore 2.57 SIC Code 2834 SIC Code Description Pharmaceutical Preparations Experian Intelliscore Percentile 2.00 % of companies score lower and have higher credit risk Established 1955 Experian Commercial IntelliscoreSM is an all-industry commercial model using business information to predict business risk. Its Sales (in millions) $65,030.00 predictiveness is among the best on the market today The objective of the Commercial Intelliscore Model is to predict seriously Employees 117,900 derogatory payment behavior. Possible score range from 0 to 100, where 0 is high risk and 100 is low risk Total OSHA Violations 18 -Liability Amount is the total dollar amount of debtor’s legal liability, OSHA is an arm of the Department of Labor that conducts inspections of company including accounts in collection, tax liens,judgments and/or bankruptcies facilities with the goal of preventing work-related injuries, illnesses and deaths. -The Number of Legal Derogatory items are the sum of Tax-Lien Worksites that do not meet health and/or safety standards at the time of inspection may Count, Bankruptcy,Judgment, Collection-Counter and UCC Derog receive an OSHA violation. Total FDA NDC Drugs 177 The total number of FDA Drugs filed in the FDA NDC Drug Database. Business Description Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field.
    [Show full text]
  • 1851022002T Hydrocortisone Ointment 0.5% Mac's
    List of Drugs Registered in Accordance with the provisions of the Food and Drugs Act and Regulations Chapter 30:01 Year 2002 DAN TRADE NAME AND MANUFACTURER COUNTRY CONDITION FORM OF OF SALE ORIGIN 1851022002T Hydrocortisone Ointment Mac’s Pharmaceuticals Jamaica Third Schedule 0.5% 1852022002T Hydrocortisone Ointment Mac’s Pharmaceuticals Jamaica Third Schedule 1% 1853022002T Hydrocortisone Cream Mac’s Pharmaceuticals Jamaica Third Schedule 0.5% 1854022002T Hydrocortisone Cream Mac’s Pharmaceuticals Jamaica Third Schedule 1% 1855022002 New-Glow Antifungal Mac’s Pharmaceuticals Jamaica Freely Solution 1856022002 Paradmol Tablets Mac’s Pharmaceuticals Jamaica Freely 1857022002 Paradmol Elixir Mac’s Pharmaceuticals & Jamaica Freely Cosmetics 1858022002 Paradmol Elixir - Alcohol Mac’s Pharmaceuticals & Jamaica Freely Free Cosmetics 1859022002T Cifran Injection Ranbaxy Laboratories India Third Schedule 200mg/100ml Limited 1739022002 Bell’s Antiseptic Cream Adams Healthcare England Freely England for Bell, Sons & Co (Druggists) Ltd. 1740022002 Menthodex Lozenges Bell, Sons & Co England Freely (Druggists) Ltd. 1741022002 Proactin Syrup Meyer Organics Ltd. India Freely 1742022002T Intaxel Injection Dabur India Ltd. India Third Schedule 100mg/17ml (Pharmaceutical Division) 1743022002T Topotel Injection Dabur India Ltd. India Third Schedule Concentrate 4mg (Pharmaceutical Division) DAN TRADE NAME AND MANUFACTURER COUNTRY CONDITION FORM OF OF SALE ORIGIN 1744022002T Cytarine Injection 100mg Dabur India Ltd. India Third Schedule (Pharmaceutical Division) 1745022002 HbRich Syrup Naxpar Lab. Pvt. Ltd. India Freely 1746022002 HbRich-300 Composite Wockhardt Limited India Freely Pack 1747022002 Juvelon Capsules Wockhardt Limited India Freely 1748022002T Aerobon Inhaler Wockhardt Limited India Third Schedule 100mcg/dose 1749022002 Ehrlich Balsam Joint Ehrlich Pharma Allgauer Germany Freely +Muscle Balsam Heilmoor Ehrlich GmbH 1750022002T FluaRIX Junior SSW Dresden a branch Germany Third Schedule Inactivated Split Influenza of SB Pharma GmbH & Vaccine - Suspension for Co.
    [Show full text]
  • Annual Report
    ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges.
    [Show full text]
  • Caring for the World . . .One Person at a Time™ Inspires and Unites the People of Johnson & Johnson
    OUR CARING TRANSFORMS 2007 Annual Report Caring for the world . .one person at a time™ inspires and unites the people of Johnson & Johnson. We embrace research and science—bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world. The people in our more than 250 companies come to work each day inspired by their personal knowledge that their caring transforms people’s lives . one person at a time. On the following pages, we invite you to see for yourself. Our Caring Transforms ON THE COVER Johnson & Johnson is founding sponsor and continues to support Safe Kids Worldwide®. For 20 years the organization has grown, now teaching prevention as a way to save children’s lives in 17 countries around the world. In Brazil, Nayra Yara da Paz de Jesus carefully washes her hands, a safe, healthy habit she and other children are learning from a local Safe Kids® program. Find out more in our story on page 22. C H A I R M A N ’ S L E T T E R To Our Shareholders Caring for the health and well-being of people throughout the world is an extraordinary business. It is a business where people are passionate about their work, because it matters. It matters to their families, to their communities and to the world. It is a business filled with tremendous opportunity for leadership and growth in the 21st century; a business where unmet needs still abound and where people around the world WILLIAM C.
    [Show full text]
  • FORM 10-Q Johnson & Johnson
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended July 4, 2021 or Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ☐ for the transition period from to Commission file number 1-3215 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 22-1024240 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 (Address of principal executive offices) Registrant’s telephone number, including area code (732) 524-0400 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☑ Yes ☐ No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☑ Yes ☐ No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
    [Show full text]
  • Annual Report 2019 to Our Shareholders
    Annual Report 2019 To Our Shareholders Vaccines and wide-spread I want to underscore the success of NanoFlu, our vaccination practices have been adjuvanted quadrivalent influenza vaccine. Earlier this instrumental in shaping our year we announced that the Phase 3 trial of NanoFlu global community by preventing achieved all primary endpoints. With these results, we devastating diseases and saving are developing a BLA package that, when approved, will millions of lives. Recent scientific allow us to bring NanoFlu to adults over 65, increasingly and technological advances offer new potential for challenged by weakened immunity. NanoFlu addresses a vaccines to address and prevent existing and emerging serious public health threat as well as a federal mandate infectious diseases. There is no better illustration of the to find better, more effective influenza vaccines. continued need for innovative vaccines than the COVID-19 pandemic we are all confronting. In addition, we remain committed to addressing the unmet medical need for an RSV vaccine for vulnerable At Novavax, our dedication to our mission necessitates populations. Other companies have joined the effort to that we focus efforts on a vaccine that can help global defeat RSV, but our RSV-F Protein vaccines are unique health authorities address, control and potentially in demonstrating potent efficacy in late stage clinical trials eradicate SARS-CoV-2, the virus responsible for for both older adults and vaccinated pregnant mothers COVID-19. We are seeking to fulfill our mission with for the protection of their infants. The results of our trials NVX-CoV2373. give us optimism that we have viable RSV vaccines, and we will continue to work with regulatory authorities and potential partners to refine clinical trial designs with the My letter to you, the stockholders of Novavax, normally goal of bringing these life-saving vaccines to the market.
    [Show full text]
  • Hatch-Waxman Act Litigation −
    Hatch-Waxman Act Litigation − Drawing on the experience of a skilled team of patent trial lawyers with an in-depth understanding of the intricacies of Food and Drug Administration (FDA) regulatory schemes, Wiley has a proven track record of guiding our clients to successful outcomes in complex Hatch-Waxman patent actions. For more than 25 years, we have effectively advocated our clients’ interests in federal and state courts across the country and before regulatory agencies in the nation’s capital. Representing both plaintiffs and defendants in high-profile and high-stakes cases, we have earned a reputation for our ability to devise and execute innovative, creative, and ultimately successful legal strategies – successes that include securing for our client in the BlackBerry patent dispute, after a successful jury trial, one of the largest patent settlements to date. Our Team Neal Seth leads a group of over 20 intellectual property attorneys with Hatch-Waxman capabilities. Our team, whose ranks include more than a dozen attorneys admitted to practice before the U.S. Patent and Trademark Office (USPTO) and four who served as judicial clerks to the U.S. Court of Appeals for the Federal Circuit, has patent litigation experience that spans a diverse range of technologies including those utilized in pharmaceuticals – such as modified/extended-release dosage forms and active pharmaceutical ingredients – biotechnology, medical devices, pesticides, and many other industries. Our Approach Wiley utilizes a cross-disciplinary approach that allows us to augment our considerable patent litigation experience with that of the firm’s deep bench of attorneys specializing in intellectual property and FDA/ regulatory matters.
    [Show full text]